ACRS Q3 2021 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ACRSAclaris Therapeutics, Inc.

$407M

Q3 2021 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$2M+14.5% YoY

Gross Profit

$560,00033.8% margin

Operating Income

-$20M-1223.3% margin

Net Income

-$21M-1274.6% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

-9.0%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$263M

Total Liabilities

$47M

Stockholders' Equity

$217M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$1M	+14.5%
Gross Profit	$560,000	$260,000	+115.4%
Operating Income	-$20M	-$10M	-93.9%
Net Income	-$21M	-$11M	-98.4%

Revenue Segments

Laboratory Research Revenue

$1M85%

Other Revenue

$244,00015%